|
|
CPDI-01 |
|
Vaxjo ID |
127 |
|
Vaccine Adjuvant Name |
CPDI-01 |
|
Adjuvant VO ID |
VO_0005330
|
|
Description |
peptide with complement receptor that induces Th1/Th2 response |
|
Stage of Development |
Research |
|
Location Licensed |
US (University of Nebraska Medical Center) |
|
Host Species for Testing |
Mouse |
|
Second Host Species for Testing |
Rabbit |
|
Components |
conformationally biased, response-selective agonist of complement component C5a65–74; conformationally biased decapeptide agonist of human C5a anaphylatoxin (YSFKPMPLaR); a molecular adjuvant and a B cell epitope of human MUC1 glycoprotein (YKQGGFLGL) |
|
Storage |
4C w/ desiccation |
|
Preparation |
when prepared with vaccine, vaccine peptide epitopes are covalently attached to N-terminus of adjuvant |
|
Function |
Type: synthetic vaccine adjuvant. Induces Th1/Th2 mixed immune profile. (Primary) Selectively activates C5aR1 receptors on mononuclear phagocytes vs neutrophils; ALSO Induces CD8 T cells, Provides innate protection, Promotes antibody affinity maturation |
| References |
(Vetro, 2021): Vaccine Adjuvant Compendium (VAC) [https://vac.niaid.nih.gov/view?id=39]
Tempero et al., 1997: Tempero RM, Hollingsworth MA, Burdick MD, Finch AM, Taylor SM, Vogen SM, Morgan EL, Sanderson SD. Molecular adjuvant effects of a conformationally biased agonist of human C5a anaphylatoxin. Journal of immunology (Baltimore, Md. : 1950). 1997; 158(3); 1377-1382. [PubMed: 9013982].
|
|
